missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Gibco™ CTS™ AIM-V™ Medium, without phenol red, without antibiotics
First commercially available serum-free formulation for proliferation and/or manipulation of T cells, dendritic cells, and other primary or immortalized cells.
Brand: Gibco™ A3830802
1215.41 EUR valid until 2024-12-31
Use promo code "21952" to get your promotional price.
This item is not returnable.
View return policy
Description
- FDA-cleared class-II medical device that is intended for human ex-vivo tissue and cell culture processing applications and is manufactured in compliance with cGMP.
- It contains L-glutamine and is formulated without phenol red and without antibiotics.
- Supplemented with human AB serum or CTS™ Immune Cell SR and various cytokines or growth factors depending on the application.
- cGMP manufactured in compliance with 21 CFR part 820
- Proven clinical use as an ancillary reagent in Provenge™ (sipuleucel-T), the first therapeutic cancer vaccine approved by the FDA [1]
- Defined serum-free formulation that contains no bovine-derived components at the primary component level.
- Can also be used to support natural killer cells combined with feeders. Each lot of CTS AIM-V Medium is pre-qualified using Jurkat cells, an immortalized human T lymphocyte line, to help ensure consistent performance.
- Available with L-glutamine, but phenol red, gentamicin sulfate, and streptomycin sulfate have been removed to meet global regulatory requirements for ancillary materials used in cell therapy manufacturing.
- Available in a 1000-mL bottle for small volume users as well as a 10-L bag for larger volume users interested in closed systems.
Specifications
| CTS AIM-V Medium is a 1 X medium without gentamicin sulphate, streptomycin sulphate, or phenol red. | |
| Stem Cell Media | |
| 10 L |
| NK Cells, T Cells, Dendritic Cells | |
| Sterile-filtered | |
| Room Temperature |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction